Simple Summary Considering the high mortality rate and the increasing spread of brain
tumors both in adulthood and in childhood, we explore the role and involvement of fibroblast …

Primary malignant bone tumors are rare sarcomas with an estimated frequency of about
2900 new cases per year; they constitute less than 0.2% of all cancers diagnosed in the …

Clinical implementation of tumor organoids for personalized medicine requires that pure
tumor organoids can be reliably established. Here, we present our experience with organoid …

A variety of analyses, including fluorescence in situ hybridization (FISH), quantitative PCR
(qPCR) and array CGH (aCGH), have been performed on a series of chordomas from 181 …

Chordoma, the molecular hallmark of which is T (brachyury), is a rare malignant bone
tumour with a high risk of local recurrence and a tumour from which metastatic disease is a …

Chordoma is a rare malignant bone tumour with a poor prognosis and limited therapeutic
options. We undertook a focused compound screen (FCS) against 1097 compounds on …

The molecular events in chordoma pathogenesis have not been fully delineated, particularly
with respect to copy number changes. Understanding copy number alterations in chordoma …

Chordoma is a rare malignant tumour of bone, the molecular marker of which is the
expression of the transcription factor, brachyury. Having recently demonstrated that silencing …

Rare cancers (RCs), which account for over 20% of cancer cases, face significant research
and treatment challenges due to their limited prevalence. This results in suboptimal …

Recent evidence suggests that the expression of brachyury is necessary for chordoma
growth. However, the mechanism associated with brachyury-regulated cell growth is poorly …